Cefepime induced acute interstitial nephritis - A case report

BMC Nephrology

Volumn 16, Issue 1, 2015, Pages

  Mac, Kathy ^a   Chavada, Ruchir ^b   Paull, Sharon ^c   Howlin, Kenneth ^a   Wong, Jeffrey ^a  

^a Department of Renal Medicine South Western Sydney Local Health District ^*  (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

Acute interstitial nephritis; Acute kidney injury; Cefepime; Nephrotoxicity

Indexed keywords

CEFEPIME; CHLORIDE; CIPROFLOXACIN; CREATININE; POTASSIUM; SODIUM; CEPHALOSPORIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CAUCASIAN; CHLORIDE BLOOD LEVEL; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; ERYTHROCYTE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY FUNCTION; LEUKOCYTE; MASTOIDITIS; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; POTASSIUM BLOOD LEVEL; PROTEINURIA; SODIUM BLOOD LEVEL; TEMPORAL BONE; TEMPORAL BONE OSTEOMYELITIS; URINALYSIS; CHEMICALLY INDUCED; ESCHERICHIA COLI INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; MICROBIOLOGY; PATHOLOGY; RARE DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ACUTE KIDNEY INJURY; CEPHALOSPORINS; CIPROFLOXACIN; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; MASTOIDITIS; MIDDLE AGED; NEPHRITIS, INTERSTITIAL; RARE DISEASES; RISK ASSESSMENT; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84924957386     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-015-0004-x     Document Type: Article

References (25)

1. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: an increasing global concern. Lancet. 2013;382(9887):170-9.
2. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743-50.
3. Schetz M, Dasta J, Goldstein S, Golper T. Drug-induced acute kidney injury. Curr Opin Crit Care. 2005;11(6):555-65.
4. Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956-61.
5. Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003;23(3):369-73.
6. Elsayed MG, Elkomy AA, Gaballah MS, Elbadawy M. Nephrotoxicity of cefepime: a new cephalosporin antibiotic in rats. J Pharmacol Pharmacother. 2014;5(1):33-8.
7. Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6(1):8-14.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
9. Barberan J, Gomis M, Sanchez B, Hernandez-Salvan J, Garcia Del Salto L, Carroquino G, et al. Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli. Rev Esp Quimioter. 2000;13(4):366-73.
10. Jauregui L, Matzke D, Scott M, Minns P, Hageage G. Cefepime as treatment for osteomyelitis and other severe bacterial infections. J Antimicrob Chemother. 1993;32(Suppl B):141-9.
11. Durand Maugard C, Lemaire Hurtel A, Gras Champel V, Hary L, Maizel, J, Prud'homme-Bernardy A, et al.: Blood and CSF monitoring of cefepime induced neurotoxicity: nine case reports. J Antimicrob Chemother, doi:10.1093/jac/dks012
12. Bugnon D, Giannoni E, Majcherczyk P, Glauser M, Moreillon P. Pitfalls in cefepime titration from human plasma:plasma- and temperature-related drug degradation in vitro. Antimicrob Agents Chemother. 2002;46(11):3654-6.
13. Tune BM, Hsu CY, Fravert D. Cephalosporin and carbacephem nephrotoxicity. Roles of tubular cell uptake and acylating potential. Biochem Pharmacol. 1996;51(4):557-61.
14. Tune BM, Fravert D. Cephalosporin nephrotoxicity. Transport, cytotoxicity and mitochondrial toxicity of cephaloglycin. J Pharmacol Exp Ther. 1980;215(1):186-90.
15. Tune BM, Fravert D. Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin. Kidney Int. 1980;18(5):591-600.
16. Bristol-Myers Squibb Company. Maxipime prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2003.
17. Tadic M, Srgurevic I, Scukanec-Spoijar M, Bozic B, Marusic S, Horvatic I, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton). 2005;10(2):103-5.
18. Malek DE, Malley LA, Slone TW, Elliott GS, Kennedy GL, Mellert W, et al. Repeated dose toxicity study (28 days) in rats and mice with N-methylpyrrolidone (NMP). Drug Chem Toxicol. 1997;20(1-2):63-77.
19. Neilson EG. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989;35:1257-70.
20. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6:461-70.
21. Michel DM, Kelly CJ. Acute interstitial nephritis. J Am Soc Nephrol. 1998;9:506-15.
22. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60(2):804-17.
23. Kida H, Abe T, Tomosugi N, Koshino Y, Yokoyama H, Hattori N. Prediction of the long-term outcome in acute interstitial nephritis. Clin Nephrol. 1984;22(2):55-60.
24. Koselj M, Kveder R, Bren AF, Rott T. Acute renal failure in patients with drug-induced acute interstitial nephritis. Ren Fail. 1993;15(1):69-72.
25. González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940-6.